North America Stem Cell Assay Market

North America Stem Cell Assay Market Size (2022 to 2027):

The North American Stem Cell Assay Market size is forecasted to grow USD 878.60 Million by 2027 from USD 356.05 Million in 2022, registering a CAGR of 19.8% between 2022 to 2027.

The growing patient population, rising incidence of chronic diseases, and initiatives by the North American governments for stem cell-based research are primarily accelerating the stem cell assay market in this region. For Instance, in the U.S., 1,735,350 new cancer cases were found as per the National Cancer Institute. Growing demand for stem cell assays, rise in the patient population admitting to the hospitals due to the increasing medical stress are increasing amount spent for the healthcare by people are some of the significant factors driving the growth of the market. An increase in the number of regenerative medicine centers and a growing number of stem cell bank supplements drive the North American stem cell assay market.

High costs associated with the research of stem cells and the behavioral issues of the market are likely to restrict the growth in the region. Scarcity of certified performers, strict administrative rules and schemes for the acceptance of the drug, and a deficit of understanding capacity pertaining to the stem cell assay market hinder the market growth in the region over the forecast period.

This research report on the North American Stem Cell Assay Market has been segmented and sub-segmented into the following categories:

By Assay Type: 

• Cell Viability & Toxicity Assays
• Purification Assays
• Differentiation Assays
• Function Assays
• Identification Assays
• Proliferation Assays
• Cell Apoptosis Assays

By Kits: 

• Adult Stem Cell Kits
• Human Embryonic Stem Cell Kits

By Application: 

• Regenerative Medicine
• Therapy Development
• Drug Discovery and Development
• Clinical Research

By End User: 

• Research institutes
• Industry research

By Country: 

• The United States
• Canada
• Rest of North America

Based on region, the USA dominates the North American Stem Cell Assays Market due to a large number of research institutes focusing on stem cell-based research and an increase in investments in the development of regenerative medicine.

The U.S follows the Canadian stem cell assays market in leading the North American region due to the growth in the acquisition of stem cell assays. Research and development activities and a surge in acceptances for clinical trials in stem cell research are necessary to grow successfully. 

Noteworthy companies dominating the North America Stem Cell Assay Market Profiled in the Report are Thermo Fisher Scientific Inc., Bio-Techne Corporation, Stem cell Technologies Inc., Merck KGaA, Promega Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Cellular Dynamics International Inc., Hemogenix, and Cell Biolabs Inc.